Evaluation Study on the Effect of Leuprolide Acetate Extended-Release Microspheres for Injection in Pediatric Precocious Puberty
Download PDF
$currentUrl="http://$_SERVER[HTTP_HOST]$_SERVER[REQUEST_URI]"

Keywords

Leuprolide acetate
Pediatric precocious puberty
Sex hormone level
Ovarian volume
Growth indicators

DOI

10.26689/jcnr.v8i12.9304

Submitted : 2024-12-08
Accepted : 2024-12-23
Published : 2025-01-07

Abstract

Objective: This study aimed to evaluate the therapeutic effects of leuprolide acetate extended-release microspheres for injection in children with pediatric precocious puberty. Methods: A total of 110 cases of pediatric precocious puberty admitted between January 2019 and December 2021 were selected and randomized into two groups using a random number table, with 55 cases in the control group and 55 cases in the experimental group. The control group received conventional treatment, while the experimental group was treated with leuprolide acetate extended-release microspheres for injection. The therapeutic effects were observed, and changes in sex hormone levels, ovarian volume, growth indices, and the incidence of adverse reactions were statistically compared between the groups. Results: The experimental group demonstrated superior outcomes in terms of sex hormone levels, ovarian volume, and growth indices compared to the control group. Additionally, the incidence of adverse reactions in the experimental group was significantly lower (P < 0.05). Conclusion: The application of leuprolide acetate extended-release microspheres for the treatment of pediatric precocious puberty is associated with improved therapeutic effects and higher safety.

References

Endocrine Genetic Metabolism Group of the Pediatrics Branch of the Chinese Medical Association, Editorial Board of the Chinese Journal of Pediatrics, 2015, Consensus on the Diagnosis and Treatment of Central Precocious Puberty (2015). Chinese Journal of Pediatrics, 53(6): 412–418.

Tirumuru SS, Arya P, Latthe P, 2012, Understanding Precocious Puberty in Girls. Obstetrician Gynaecologist, 14: 121–129. https://doi.org/10.1111/j.1744-4667.2012.00094.x

Yang M, Tang S, Xin Y, 2020, A Case Report of a Patient with Precocious Puberty and Karyotype 45, X/46, XX/47, XXX Turner Syndrome. Chinese Journal of Evidence-Based Pediatrics, 15(6): 463–466.

Wang M, Gao Y, Li X, et al., 2019, Effectiveness and Safety of GnRHa Combined with rhGH in Improving Predicted Adult Height in Children with Idiopathic Central Precocious Puberty at Different Ages. China Maternal and Child Health, 34(16): 3703–3704.

Xu L, Hong Q, Fang Y, 2022, Clinical Efficacy of Treprostinil in Girls with Idiopathic Central Precocious Puberty and Effect on Bone Age. International Journal of Medicine and Health, 28(6): 829–832.

Ma X, Ni J, Yang L, et al., 2020, Long-Term Effects of GnRHa Treatment on Children with Idiopathic Central Precocious Puberty and Rapidly Progressive Precocious Puberty. Chinese Journal of Endocrinology and Metabolism, 36(1): 58–62.

Chen J, Lin Y, Zhou Y, et al., 2020, Analysis of Clinical Regression and Risk Factors of Central Precocious Puberty in Girls with Premature Breast Development. Zhejiang Medicine, 42(8): 811–814.

Chu Z, Jiang H, Wu Q, 2021, Meta-analysis of Gonadotropin-Releasing Hormone Analog Treatment on the Improvement of Adult Lifelong Height in Children with Central Precocious Puberty and Rapidly Progressive Puberty. Chinese Journal of Contemporary Pediatrics, 11: 1161–1168.

Guaraldi F, Beccuti G, Gori D, et al., 2016, Management of Endocrine Disease: Long-Term Outcomes of the Treatment of Central Precocious Puberty. Eur J Endocrinol, 174(3): R79–R87. https://doi.org/10.1530/EJE-15-0590

Liang Y, Wei H, Li J, et al., 2015, Effect of GnRHa 3.75 mg Subcutaneously Every 6 Weeks on Adult Height in Girls with Idiopathic Central Precocious Puberty. J Pediatr Endocrinol Metab, 28(7–8): 839–846. https://doi.org/10.1515/jpem-2014-0305

Wang XP, Xu X, Jiang L, et al., 2020, Efficacy of Recombinant Human Growth Hormone Combined with Leuprolide in the Treatment of Girls with Idiopathic Central Precocious Puberty. Journal of Pediatric Pharmacy, 26(7): 17–20.

Feng Y, 2020, Evaluation of the Efficacy of Leuprolide Extended-Release Microspheres in Children with Central Precocious Puberty. Wisdom Health, 6(24): 50–51 + 54.

Yu Y, Hou W, Ding H, et al., 2021, Observations on the Efficacy of Dangdaji Yuanyuan Capsule Combined with Trenbolone Acetate in the Treatment of Idiopathic Pivotal Precocious Puberty in Female Children. Journal of Xinxiang Medical College, 38(11): 1048–1052.

Luo X, Liang Y, Hou L, et al., 2021, Long-Term Efficacy and Safety of Gonadotropin-Releasing Hormone Analog Treatment in Children with Idiopathic Central Precocious Puberty: A Systematic Review and Meta-Analysis. Clin Endocrinol (Oxf), 94(5): 786–796. https://doi.org/10.1111/cen.14410

Fu J, Zhang J, Chen R, et al., 2020, Long-Term Outcomes of Treatments for Central Precocious Puberty or Early and Fast Puberty in Chinese Girls. J Clin Endocrinol Metab, 105(3): dgz027. https://doi.org/10.1210/clinem/dgz027

Ma X, Ni J, Yang L, et al., 2020, Long-Term Effects of GnRHa Treatment on Children with Idiopathic Central Precocious Puberty and Rapidly Progressive Precocious Puberty. Chinese Journal of Endocrinology and Metabolism, 36(1): 58–62.